Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation
The only curative therapy for end-stage heart failure is orthotopic allogeneic heart transplantation. This therapy has extended the survival of patients worldwide but is limited due to the scarcity of donor organs. Potential alternative donor sources of organs for transplantation include genetically...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Houston Methodist DeBakey Heart & Vascular Center
2025-05-01
|
| Series: | Methodist DeBakey Cardiovascular Journal |
| Subjects: | |
| Online Access: | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1590 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128286636572672 |
|---|---|
| author | Daniel J. Garry Mary G. Garry Hiromitsu Nakauchi Hideki Masaki David H. Sachs Joshua I. Weiner Daniel Reichart Eckhard Wolf |
| author_facet | Daniel J. Garry Mary G. Garry Hiromitsu Nakauchi Hideki Masaki David H. Sachs Joshua I. Weiner Daniel Reichart Eckhard Wolf |
| author_sort | Daniel J. Garry |
| collection | DOAJ |
| description | The only curative therapy for end-stage heart failure is orthotopic allogeneic heart transplantation. This therapy has extended the survival of patients worldwide but is limited due to the scarcity of donor organs. Potential alternative donor sources of organs for transplantation include genetically-modified (GM) large animal donors (ie, xenografts) and human organs developed in large animal hosts. These strategies utilize gene editing and somatic cell nuclear transfer technologies to engineer partially or completely humanized organs. Preclinical xenotransplantation studies of GM pig hearts into baboons have already provided an important clinical foundation, as two patients have received cardiac xenografts from GM pigs and have survived for up to 2 months. Additional issues need to be addressed in order for patients to survive more than 1 year, which would make these strategies clinically applicable. Thus, in combination with immunosuppression agents, xenogeneic and exogenic organ sources hold tremendous promise for an unlimited and transformative supply of organs for transplantation. |
| format | Article |
| id | doaj-art-56279a64cfc04ffdb2a86d5d357dc2ab |
| institution | OA Journals |
| issn | 1947-6108 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Houston Methodist DeBakey Heart & Vascular Center |
| record_format | Article |
| series | Methodist DeBakey Cardiovascular Journal |
| spelling | doaj-art-56279a64cfc04ffdb2a86d5d357dc2ab2025-08-20T02:33:23ZengHouston Methodist DeBakey Heart & Vascular CenterMethodist DeBakey Cardiovascular Journal1947-61082025-05-01213929910.14797/mdcvj.15901568Allogeneic, Xenogeneic, and Exogenic Hearts for TransplantationDaniel J. Garry0https://orcid.org/0000-0002-8970-7365Mary G. Garry1https://orcid.org/0000-0002-7958-5560Hiromitsu Nakauchi2https://orcid.org/0000-0002-8122-2566Hideki Masaki3https://orcid.org/0000-0001-7615-5314David H. Sachs4https://orcid.org/0000-0001-9588-8580Joshua I. Weiner5https://orcid.org/0000-0003-3780-1875Daniel Reichart6https://orcid.org/0000-0002-8559-5888Eckhard Wolf7https://orcid.org/0000-0002-0430-9510Stem Cell Institute, IN; Lillehei Heart Institute, University of Minnesota, Minneapolis, MinnesotaStem Cell Institute, IN; Lillehei Heart Institute, University of Minnesota, Minneapolis, MinnesotaUniversity of Tokyo, Tokyo; Institute of Science Tokyo (formerly Tokyo Medical and Dental University), Tokyo, JP; Stanford University School of Medicine, Stanford, CaliforniaUniversity of Tokyo, Tokyo; Institute of Science Tokyo (formerly Tokyo Medical and Dental University) TokyoVagelos College of Physicians and Surgeons, Columbia University, New York, New York; Massachusetts General Hospital, Boston, MassachusettsVagelos College of Physicians and Surgeons, Columbia University, New York, New YorkUniversity Hospital, LMU Munich, Munich; Gene Center and Center for Innovative Medical Models (CiMM); Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, MunichGene Center and Center for Innovative Medical Models (CiMM); Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, MunichThe only curative therapy for end-stage heart failure is orthotopic allogeneic heart transplantation. This therapy has extended the survival of patients worldwide but is limited due to the scarcity of donor organs. Potential alternative donor sources of organs for transplantation include genetically-modified (GM) large animal donors (ie, xenografts) and human organs developed in large animal hosts. These strategies utilize gene editing and somatic cell nuclear transfer technologies to engineer partially or completely humanized organs. Preclinical xenotransplantation studies of GM pig hearts into baboons have already provided an important clinical foundation, as two patients have received cardiac xenografts from GM pigs and have survived for up to 2 months. Additional issues need to be addressed in order for patients to survive more than 1 year, which would make these strategies clinically applicable. Thus, in combination with immunosuppression agents, xenogeneic and exogenic organ sources hold tremendous promise for an unlimited and transformative supply of organs for transplantation.https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1590orthotopic heart transplantationexogenesisxenotransplantationgene editingsomatic cell nuclear transferblastocyst complementation |
| spellingShingle | Daniel J. Garry Mary G. Garry Hiromitsu Nakauchi Hideki Masaki David H. Sachs Joshua I. Weiner Daniel Reichart Eckhard Wolf Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation Methodist DeBakey Cardiovascular Journal orthotopic heart transplantation exogenesis xenotransplantation gene editing somatic cell nuclear transfer blastocyst complementation |
| title | Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation |
| title_full | Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation |
| title_fullStr | Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation |
| title_full_unstemmed | Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation |
| title_short | Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation |
| title_sort | allogeneic xenogeneic and exogenic hearts for transplantation |
| topic | orthotopic heart transplantation exogenesis xenotransplantation gene editing somatic cell nuclear transfer blastocyst complementation |
| url | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1590 |
| work_keys_str_mv | AT danieljgarry allogeneicxenogeneicandexogenicheartsfortransplantation AT maryggarry allogeneicxenogeneicandexogenicheartsfortransplantation AT hiromitsunakauchi allogeneicxenogeneicandexogenicheartsfortransplantation AT hidekimasaki allogeneicxenogeneicandexogenicheartsfortransplantation AT davidhsachs allogeneicxenogeneicandexogenicheartsfortransplantation AT joshuaiweiner allogeneicxenogeneicandexogenicheartsfortransplantation AT danielreichart allogeneicxenogeneicandexogenicheartsfortransplantation AT eckhardwolf allogeneicxenogeneicandexogenicheartsfortransplantation |